Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;12(3):e200386.
doi: 10.1212/NXI.0000000000200386. Epub 2025 Mar 14.

Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis

Affiliations

Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis

Sarah Demortiere et al. Neurol Neuroimmunol Neuroinflamm. 2025 May.

Abstract

Background and objectives: A simple, quick, and reproducible procedure for distinguishing multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD) at inaugural optic neuritis (ION) could be highly valuable in guiding early management.

Methods: We included all adults admitted to the MS center of Marseille for ION between March 2016 and April 2024, with CSF analysis including the kappa free light chain (K-FLC) index. Receiver operating characteristic curves were used to measure the diagnostic ability of the K-FLC index.

Results: Two hundred twenty-seven adults were admitted for ION; 210 (93%) had a K-FLC index measurement. MS was diagnosed in 84 (40%); clinically isolated syndrome suggestive of MS in 77 (36.5%), including 20 with future conversion to MS (CISwc); MOGAD in 26 (12.5%); NMOSD in 13 (6%); and other inflammatory disorders in 10 (5%). A K-FLC index ≥6.7 differentiated MS/CISwc from other diagnoses with specificity 86% and sensitivity 95% (area under the curve [AUC] 0.94). A K-FLC index <4.9 differentiated MOGAD from other diagnoses with specificity 63% and sensitivity 92% (AUC 0.78) and MOGAD from MS/CISwc with specificity 96% and sensitivity 92% (AUC 0.97). Among all patients, 93 (44%) had a K-FLC index <4.9: 24 of these (26%) had MOGAD and 5 (5.5%) MS/CISwc. Among the remaining patients with a K-FLC index ≥4.9 (n = 117), 2 (1.7%) had MOGAD (K-FLC index of 7.9 and 16.2) and 99 (85%) MS/CISwc. Among patients with normal MRI (n = 96), 73 (76%) had a K-FLC index <4.9: 22 of these (30%) had MOGAD, and none showed conversion to MS. Among the remaining patients with a K-FLC index ≥4.9 (n = 23), 2 (8.5%) had MOGAD and 7 (30.5%) showed conversion to MS. The K-FLC index did not differentiate NMOSD from other diagnoses and only moderately differentiated NMO from MS/CISwc (AUC 0.80).

Discussion: The K-FLC index is an accessible biomarker to guide early diagnosis in patients with ION. The probability of MOGAD in patients with ION and a K-FLC index ≥4.9 is low even in case of normal brain/spinal cord MRI.

Classification of evidence: This study provides Class II evidence that for patients with ION, the K-FLC index can distinguish between MS/CISwc and MOGAD.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Comparison of CSF Findings Between Groups
Violin plots of (A) IgG index values for each group at inaugural optic neuritis and (B) kappa free light chain index values for each group.
Figure 2
Figure 2. Discrimination Between MOGAD and MS/CISwc
ROC curve for the IgG index gave an AUC of 0.88 with a best cutoff of 0.64. ROC curve for the K-FLC index gave an AUC of 0.97 with a best cutoff of 4.9. AUC = area under the curve; MOGAD = =myelin oligodendrocyte glycoprotein antibody–associated disease; ROC = receiver operating characteristic.

References

    1. Wingerchuk DM, Banwell B, Bennett JL, et al. . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729 - DOI - PMC - PubMed
    1. Banwell B, Bennett JL, Marignier R, et al. . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8 - DOI - PubMed
    1. Bennett JL, Costello F, Chen JJ, et al. . Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22(1):89-100. doi:10.1016/S1474-4422(22)00187-9 - DOI - PubMed
    1. Marignier R, Hacohen Y, Cobo-Calvo A, et al. . Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762-772. doi:10.1016/S1474-4422(21)00218-0 - DOI - PubMed
    1. Maillart E, Deiva K, Marignier R. Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodies. Curr Opin Neurol. 2024;37(3):338-344. doi:10.1097/WCO.0000000000001265 - DOI - PubMed

Substances